BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21533120)

  • 1. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes.
    Rogue A; Lambert C; Jossé R; Antherieu S; Spire C; Claude N; Guillouzo A
    PLoS One; 2011 Apr; 6(4):e18816. PubMed ID: 21533120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
    Rogue A; Renaud MP; Claude N; Guillouzo A; Spire C
    Toxicol Appl Pharmacol; 2011 Jul; 254(1):18-31. PubMed ID: 21515302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
    Guo L; Zhang L; Sun Y; Muskhelishvili L; Blann E; Dial S; Shi L; Schroth G; Dragan YP
    Mol Divers; 2006 Aug; 10(3):349-60. PubMed ID: 17031537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
    Kalliora C; Drosatos K
    J Cardiovasc Pharmacol; 2020 Nov; 76(5):514-526. PubMed ID: 33165133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
    Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
    Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory properties of a dual PPARgamma/alpha agonist muraglitazar in in vitro and in vivo models.
    Paukkeri EL; Leppänen T; Lindholm M; Yam MF; Asmawi MZ; Kolmonen A; Aulaskari PH; Moilanen E
    Arthritis Res Ther; 2013 Apr; 15(2):R51. PubMed ID: 23594962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
    Guo L; Fang H; Collins J; Fan XH; Dial S; Wong A; Mehta K; Blann E; Shi L; Tong W; Dragan YP
    BMC Bioinformatics; 2006 Sep; 7 Suppl 2(Suppl 2):S18. PubMed ID: 17118139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
    Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
    PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress.
    Sekulic-Jablanovic M; Petkovic V; Wright MB; Kucharava K; Huerzeler N; Levano S; Brand Y; Leitmeyer K; Glutz A; Bausch A; Bodmer D
    PLoS One; 2017; 12(11):e0188596. PubMed ID: 29182629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
    D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators.
    Tamura K; Ono A; Miyagishima T; Nagao T; Urushidani T
    J Toxicol Sci; 2006 Dec; 31(5):471-90. PubMed ID: 17202761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
    Nakano Y; Arima T; Tobita Y; Uchiyama M; Shimizu A; Takahashi H
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1.
    König B; Koch A; Spielmann J; Hilgenfeld C; Hirche F; Stangl GI; Eder K
    Eur J Pharmacol; 2009 Mar; 605(1-3):23-30. PubMed ID: 19248225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications.
    Mandal S; Faizan S; Raghavendra NM; Kumar BRP
    Mol Divers; 2023 Dec; 27(6):2605-2631. PubMed ID: 36437421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism.
    Sharifpanah F; Wartenberg M; Hannig M; Piper HM; Sauer H
    Stem Cells; 2008 Jan; 26(1):64-71. PubMed ID: 17951219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
    Balakumar P; Mahadevan N; Sambathkumar R
    Curr Mol Pharmacol; 2019; 12(3):195-201. PubMed ID: 30636619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.